Reconstructed dose and geometric coverage for tight margins using intrafraction re-planning on an integrated magnetic resonance imaging and linear accelerator system for prostate cancer patients

利用集成磁共振成像和直线加速器系统进行分次内重新计划,重建前列腺癌患者的剂量和几何覆盖范围,以实现小边界治疗。

阅读:1

Abstract

BACKGROUND AND PURPOSE: A sub-fractionation workflow enables a substantial reduction in planning target volume (PTV) margin in prostate cancer (PCa) patients by reducing systematic motion during magnetic resonance (MR)-guided radiotherapy. This study assessed geometric and reconstructed dose outcomes in patients treated with a tight-margin sub-fractionation workflow on a combined linear accelerator with a 1.5 T MRI scanner (MR-Linac). MATERIALS AND METHODS: We evaluated the sub-fractionation workflow with tight margins (2-3 mm) on 128 PCa patients who completed treatment with 5 × 7.25 Gy (36.25 Gy total dose). A traffic light protocol was applied based on residual motions to detect patients with unexpectedly large motions. When 'red' traffic light criteria were met, plans with larger margins (5 mm isotropic) were adopted for subsequent fractions. Intra- and inter-fraction dose accumulation was performed via an in-house developed deformable image registration algorithm. RESULTS: A total of 89 % (114/128) of patients completed treatment with the initial tight margins. The mean 3D intrafraction shifts were 1.0 mm (SD: 0.6 mm) in the group with the tight margins and 1.9 mm (SD: 1.5 mm) in the patient group who switched to large margins. The median accumulated D99% was 34.9 Gy (interquartile range: 34.0-35.3 Gy) for patients with prostate shifts who switched to larger margins. In 57 % (8/14) of these patients, the accumulated D99% was above the threshold of 34.4 Gy. CONCLUSIONS: Tight margins of 2-3 mm can be safely applied for at least 95 % (122/128) of the PCa patients undergoing a sub-fractionation workflow on a 1.5 T MR-linac.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。